Key Takeaways
- Aprea Therapeutics and Pinnacle Medicines secured a total of $119 million from investors.
- The Philadelphia life sciences sector has raised over $850 million through venture deals.
- Funding will support research for Aprea and advance cardiometabolic disease and immunology programs for Pinnacle.
Aprea Therapeutics Raises $30 Million
Aprea Therapeutics, based in the Pennsylvania Biotechnology Center, has successfully raised $30 million through a private stock placement. The round was spearheaded by Soleus Capital and attracted participation from new investors, including Vestal Point Capital and Squadron Capital Management, along with existing investors and insiders. The funds raised will support the company’s research and development efforts and address general corporate needs.
Pinnacle Medicines Closes $89 Million in Series B Financing
On the other hand, Pinnacle Medicines, which operates in Doylestown but is headquartered in Shanghai, recently wrapped up a Series B funding round, securing $89 million. This financing round was co-led by Foresite Capital and LAV, with contributions from multiple investors, including Hankang Capital, Quan Capital, RA Capital Management, Logos Capital, and OrbiMed. Funds raised will be directed towards advancing Pinnacle’s programs in cardiometabolic diseases and immunology.
Collectively, the investments in Aprea and Pinnacle highlight the growing interest and financial activity in the life sciences sector within the Philadelphia region. Over the past years, this sector has garnered significant investment, totaling over $850 million through various capital deals, underscoring the vibrancy and potential of life sciences in the area.
The content above is a summary. For more details, see the source article.